| Date | Title | Description |
| 12.08.2026 | Silent Cancer Therapeutics Market Size to Reach USD 36.52 Billion by 2035, Driven by Precision Oncology and Advanced Cancer Therapies | Overview
According to DataM Intelligence, the global silent cancer therapeutics market size was valued at USD 15.86 billion in 2025 and is forecast to reach USD 36.52 billion by 2035, expanding at a CAGR of 8.7% during 2026 to 2035. The mar... |
| 04.08.2026 | Merck hikes revenue outlook as new drug sales grow, but cuts profit guidance due to deal charges | Merck beat second-quarter estimates and hiked its revenue outlook, as a slate of new products showed strong growth.
But the pharmaceutical giant cut its profit guidance due to a charge tied to its acquisition of biotech company Terns Pharma... |
| 16.04.2026 | Early-stage funding slumps toward post-pandemic low, piling more pressure on biotech startups | A slow start to 2026 has put first-time biotech financings on course for their worst year since before the pandemic, reducing the already limited funding opportunities available for startups.
The data come from J.P. Morgan’s first-quarter b... |
| 27.03.2026 | Global Crossroads: Pharma Shifts and Markets Sway | Wall Street navigates intense volatility. Geopolitical tensions from the ongoing Iran conflict drive market swings. Oil prices ease on perceived de-escalation, yet regional attacks persist. Global stocks post fragile gains. Amid this turbul... |
| 27.03.2026 | Novartis shells out $2 billion for immunology biotech Excellergy, in second multi-billion dollar deal in a week | Novartis’ acquisition of U.S.-based Excellergy will add an early-stage drug candidate Exl-111 to the company’s existing allergy portfolio.
It comes just a week after Novartis announced it is acquiring Synnovation subsidiary Pikavation Thera... |
| 25.03.2026 | Stocks rise and oil prices ease as Wall Street keeps yo-yoing because of the war with Iran | Getting your Trinity Audio player ready...
By STAN CHOE, AP Business Writer
NEW YORK (AP) — Hopes for a possible end to the war with Iran pushed stocks higher on Wall Street Wednesday, while oil prices eased. Related Articles
Europe’s top c... |
| 25.03.2026 | 5 Things to Know
U.S.-Iran negotiations, Meta trial verdict, OpenAI shuts Sora and more in Morning Squawk | This is CNBC’s Morning Squawk newsletter. Subscribe here to receive future editions in your inbox.
Happy Wednesday. I spent yesterday evening at a market technicals event and then went to watch the “Hannah Montana 20th Anniversary Special.”... |
| 25.03.2026 | Merck to buy Terns Pharmaceuticals for $6.7 billion to boost cancer pipeline | Merck will acquire Terns for $53 per share in cash, amounting to an equity value of about $6.7 billion.
This is the third multibillion-dollar acquisition for Merck over the past year as it looks to bulk up its portfolio ahead of its best-se... |
| 16.12.2025 |
Cramer’s Lighting Round: ‘Be careful’ with Lumen Technologies | Monday - Friday, 6:00 - 7:00 PM ET
It’s that time again! “Mad Money” host Jim Cramer rings the lightning round bell, which means he’s giving his answers to callers’ stock questions at rapid speed.
Unusual Machines: “Drone technology. Highly... |
| 12.11.2025 | Alentis Strengthens Management Team with Key Appointments | Alentis Therapeutics (“Alentis”), a clinical-stage biotechnology company developing first-in-class therapies targeting claudin-1 for a range of fibrosis and oncology indications, today announced the appointment of Bryan Yoon as General Coun... |
| 10.09.2024 | Дешевле, эффективнее и без уколов. Новый «Оземпик» на подходе | Кажется, что человечество стало еще на шаг ближе к исполнению «ленивых желаний». Никаких тренировок, никакой диеты – закинул таблетку и почти безвредно похудел. И если препарат Оземпик стоил дорого и вводился иглой, то теперь на рынке новый... |
| 10.09.2024 | Terns Announces Pricing of Upsized $150.15 Million Public Offering | FOSTER CITY, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address... |
| 05.08.2024 | Terns Pharmaceuticals Reports Second Quarter 2024 Financial Results and Corporate Updates | Top-line data from Phase 1 trial of TERN-601 (oral GLP-1) for obesity expected in September 2024
Interim data from initial dose escalation cohorts of Phase 1 CARDINAL trial evaluating TERN-701 (allosteric BCR-ABL) in chronic myeloid leukemi... |
| 11.03.2024 | Terns Pharmaceuticals Announces Orphan Drug Designation Granted to TERN-701 for the Treatment of Chronic Myeloid Leukemia | - |
| 11.03.2024 | Terns Pharmaceuticals Announces Orphan Drug Designation Granted to TERN-701 for the Treatment of Chronic Myeloid Leukemia | FOSTER CITY, Calif., March 11, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address... |
| 07.03.2024 | Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4) | - |
| 21.12.2022 | Terns Announces Pricing of $75 Million Public Offering | FOSTER CITY, Calif., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") TERN, a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates t... |
| 20.12.2022 | Terns Announces Pricing of $75 Million Public Offering | - |
| 12.08.2022 | Terns Announces $65 Million Oversubscribed Offering | FOSTER CITY, Calif., Aug. 12, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address ... |
| 28.02.2021 | 3 New IPOs Trending Higher Heading Into March | February was an active month for IPOs. |
| 07.01.2021 | Terns Pharmaceuticals, Inc. announced that it has received $97.703068 million in funding from a group of investors | On January 7, 2021, Terns Pharmaceuticals, Inc. closed the transaction. The company has received $10,703,068 in its second and final tranche from 18 investors. The company has raised $97,703,068 in the transaction. |
| 06.01.2021 | Terns Pharmaceuticals Raises $87M in Series C |
FOSTER CITY, CA, Terns Pharmaceuticals has closed an $87 million Series C financing led by Deerfield Management Company.
>> Click here for more funding data on Terns Pharmaceuticals
>> To export Terns Pharmaceuticals funding... |
| 05.01.2021 | Lilly-backed Terns raises $87M for multi-front assault on NASH
W h i t e p a p e r
Weighing the Costs: | Terns Pharmaceuticals has raised $87 million to fund clinical trials of its three lead nonalcoholic steatohepatitis (NASH) candidates. Deerfield Management led the round with assists from investors including Eli Lilly.
Sponsored by Agilent ... |
| 05.01.2021 | Lilly-backed Terns raises $87M for multi-front assault on NASH | Terns Pharmaceuticals has raised $87 million to fund clinical trials of its three lead nonalcoholic steatohepatitis (NASH) candidates. Deerfield Management led the round with assists from investors including Eli Lilly.
Stumbles by Intercept... |
| 05.01.2021 | TERNS CLOSES $87 MILLION SERIES C FINANCING TO ADVANCE NASH PORTFOLIO | - |
| 05.01.2021 | Terns raises $87M to advance trials of NASH drugs | Terns said it will use the proceeds of its series C round to advance clinical trials of its three NASH candidates.
The furthest along is TERN-101, a liver-directed non-bile acid farnesoid X receptor (FXR) agonist. Terns currently has 96 pat... |
| 30.10.2018 | Terns Pharmaceuticals Completes $80 Million Series B Financing to Advance Pipeline of Drugs to Treat NASH and Cancer | - |
| 30.10.2018 | Terns scores $80M in Series B financing led by Vivo, OrbiMed | Weidong Zhong
Transpacific biotech upstart Terns Pharmaceuticals, which is focused on developing treatments for NASH and cancer, has closed $80 million in Series B financing as it prepares to shepherd its lead experim... |
| 30.10.2018 | Chinese-American startup Terns Pharmaceuticals raises $80M for NASH, cancer drugs | The company – which is based in San Mateo, California, and Shanghai – said it plans to use the money to develop its two lead drug candidates, TERN-101 and TERN-201, which it expects to enter into the clinic in the first half of next year. B... |
| 04.04.2018 | Terns emerges with all 3 of Lilly’s NASH programs and $30M from Lilly Asia Ventures | The hot nonalcoholic steatohepatitis (NASH) arena has a new player, Terns Pharmaceuticals, and it has already got three programs from Eli Lilly and a $30 million series A backed by Lilly Asia Ventures.
Announced a week before the EASL liver... |
| - | The weight loss drug market may soon get more crowded. Here are the companies trying to enter the booming space | Drugmakers have been scrambling to join a two-horse race to make highly sought after weight loss drugs.
There may still be room for lesser-known competitors like the privately held Boehringer Ingelheim, and smaller public companies such as ... |
| - | Terns raises $87M to advance trials of NASH drugs | After gaining a big backer in Eli Lilly & Co. two years ago, Terns Pharmaceuticals now has two NASH candidates in clinical trials. The startup, headquartered in Foster City, Calif., recently raised $87 million to push forward in a compe... |
| - | Chinese-American startup Terns Pharmaceuticals raises $80M for NASH, cancer drugs | A company focused on cancers and advanced fatty liver disease has completed its latest round of venture capital financing.
Terns Pharmaceuticals said Tuesday that it had closed an $80 million Series B funding round, led by Vivo Capital and ... |
